Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Details New Operational Rules for Conditional Approvals from May
Japan’s Ministry of Health, Labor and Welfare (MHLW) has issued new guidance on how the country’s conditional approval system for pharmaceuticals will be operated under the revised Pharmaceuticals and Medical Devices (PMD) Act, which takes effect in May. In a…
To read the full story
Related Article
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- MHLW Issues 15 Notices Ahead of PMD Act Amendment
March 2, 2026
REGULATORY
- MHLW Panel Voices Disappointment over Efluelda Launch Delay
July 24, 2026
- Japan Sees Limited Impact from Planned US Tariffs on Generics
July 23, 2026
- MHLW Vaccine Panel Advances Mumps, RSV, HPV Discussions
July 23, 2026
- Japan Moves to Bar Duplicate IRB Reviews under Single-IRB Framework
July 23, 2026
- Chuikyo OKs NHI Listing for Cuorips’ iPSC-Based Riheart
July 23, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…